Company Overview
About Deep Genomics
Deep Genomics is a biopharmaceutical company founded in 2015 by Brendan Frey and headquartered in Toronto, Ontario, Canada. The company applies artificial intelligence to the challenge of RNA biology — developing a proprietary AI Workbench platform that can predict how genetic variants affect RNA splicing, processing, and gene expression. This computational capability allows Deep Genomics to identify disease-causing mutations that alter RNA function and to design antisense oligonucleotide (ASO) and other RNA-based therapies that correct those molecular defects — a process that traditionally requires years of manual biological experimentation.
Business Model & Competitive Advantage
Deep Genomics' approach is differentiated by the depth of its AI training: the company has generated proprietary biological datasets measuring the functional effects of millions of genetic variants on RNA biology, creating training data that enables its models to make highly accurate predictions about the molecular consequences of disease-associated mutations. This AI-biology flywheel — where experimental data trains better AI models, which design better experiments — allows Deep Genomics to advance drug programs faster and with greater confidence than traditional RNA therapeutics approaches. The company has raised over $180M in total funding, including investments from GV (Google Ventures), 8VC, and others, as well as a 2022 partnership with Alphabet.
Competitive Landscape 2025–2026
Deep Genomics has multiple preclinical programs targeting rare genetic diseases including Wilson disease and Batten disease, conditions caused by specific genetic mutations that disrupt RNA processing. The company operates at the intersection of AI and RNA therapeutics — a convergence that has attracted significant capital given the clinical validation of RNA medicines following the success of COVID-19 mRNA vaccines and approved ASO drugs for conditions including spinal muscular atrophy (SMA).
Key Differentiators
Emerging Innovator
Deep Genomics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Deep Genomics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Deep Genomics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Deep Genomics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Deep Genomics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →